RU2014144700A - Methods for influencing UBE3A gene expression - Google Patents
Methods for influencing UBE3A gene expression Download PDFInfo
- Publication number
- RU2014144700A RU2014144700A RU2014144700A RU2014144700A RU2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- gene
- ube3a
- influencing
- ube3a gene
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ воздействия на экспрессию гена UBE3A в клетках пациента, включающий приведение в контакт указанных клеток с одним или несколькими антисмысловыми олигонуклеотидами, где последовательность, по меньшей мере, на 70% идентична последовательности указанного гена.2. Способ по п.1, где экспрессию повышают.3. Синтетический олигонуклеотид, имеющий последовательность, на 70% идентичную последовательности гена UBE3A.4. Синтетический олигонуклеотид по п.3, где олигонуклеотид имеет последовательность, на 80% идентичную последовательности гена UBE3A.5. Композиция, содержащая один или более синтетических олигонуклеотидов по п.3.6. Способ лечения заболевания, связанного с геном UBE3A, включающий введение пациенту эффективной дозы одного ли нескольких олигонуклеотидов по п.3.1. A method of influencing the expression of a UBE3A gene in a patient’s cells, comprising contacting said cells with one or more antisense oligonucleotides, wherein the sequence is at least 70% identical to the sequence of the indicated gene. The method of claim 1, wherein the expression is enhanced. A synthetic oligonucleotide having a sequence 70% identical to the sequence of the UBE3A.4 gene. The synthetic oligonucleotide according to claim 3, wherein the oligonucleotide has a sequence that is 80% identical to the sequence of the UBE3A.5 gene. A composition comprising one or more synthetic oligonucleotides according to claim 3.6. A method of treating a disease associated with the UBE3A gene, comprising administering to the patient an effective dose of one or more oligonucleotides according to claim 3.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014144700A RU2014144700A (en) | 2014-11-07 | 2014-11-07 | Methods for influencing UBE3A gene expression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014144700A RU2014144700A (en) | 2014-11-07 | 2014-11-07 | Methods for influencing UBE3A gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014144700A true RU2014144700A (en) | 2016-06-10 |
Family
ID=56114696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014144700A RU2014144700A (en) | 2014-11-07 | 2014-11-07 | Methods for influencing UBE3A gene expression |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2014144700A (en) |
-
2014
- 2014-11-07 RU RU2014144700A patent/RU2014144700A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
NI201600071A (en) | AUTOTAXIN INHIBITOR COMPOUNDS | |
BR112016022742A2 (en) | compositions and methods for modulating growth hormone receptor expression | |
BR112017004349A2 (en) | globin gene therapy for treatment of hemoglobinopathies | |
AR101312A1 (en) | COMBINATIONS OF BET INHIBITORS AND INHIBITORS OF TIROSINA QUINASA DE BRUTON | |
BR112015023439A2 (en) | combination of cancer treatments using micro-ovens and egfr-tki inhibitors | |
TR201818825T4 (en) | LNCRNAS FOR THE TREATMENT AND DIAGNOSIS OF CARDIAC HYPERTROPHY | |
BR112018003526A2 (en) | methods of treating inflammatory diseases | |
NI201600070A (en) | AUTOTAXIN TETRAYCLIC INHIBITORS | |
EA201791471A1 (en) | METHODS OF APPLICATION OF ANTI-SMART OLIGONUCLEOTIDE SMAD7 | |
BR112019005040A2 (en) | pridopidine application for rett syndrome treatment | |
MX2015012444A (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens. | |
BR112018008931A8 (en) | "compounds for treating hypoproliferative disorders" | |
UY35328A (en) | TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD | |
CY1122708T1 (en) | OXA-DIAZASPIRE COMPOUNDS WITH ACTION AGAINST PAIN | |
BR112018010736A2 (en) | antisense oligonucleotides against il-34 and methods of using them | |
MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
RU2014144700A (en) | Methods for influencing UBE3A gene expression | |
RU2014146616A (en) | Methods for influencing SNRPN gene expression | |
RU2014142752A (en) | Methods for influencing lactase gene expression | |
RU2014142756A (en) | Methods for influencing D4DR gene expression | |
RU2014142755A (en) | Methods for influencing CYP17 gene expression | |
RU2014141738A (en) | Methods for influencing CFTR gene expression | |
BR112017011513A2 (en) | treatment of eye conditions using progenitor cells | |
RU2014144094A (en) | Methods for influencing CREBBP gene expression |